VANI Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.420

Open

1.320

VWAP

1.34

Vol

11.55M

Mkt Cap

116.42M

Low

1.260

Amount

15.52M

EV/EBITDA(TTM)

--

Total Shares

86.24M

EV

92.36M

EV/OCF(TTM)

--

P/S(TTM)

--

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.

Show More

Events Timeline

(ET)

2026-07-07

08:00:00

Vivani Medical Signs Agreement with Novo Nordisk to Evaluate NPM-139

2026-07-02 (ET)

2026-07-02

08:30:00

Vivani Medical Enters Merger Agreement with ClearOne

2026-07-02

08:30:00

ClearOne Enters Merger Agreement with Vivani Medical

2026-06-25 (ET)

2026-06-25

08:00:00

Vivani Medical Receives Approval for NPM-139 Clinical Trial in Australia

2026-01-29 (ET)

2026-01-29

07:40:00

Vivani Medical Subsidiary Presents Orion Visual Cortical Prosthesis Study Results

2025-11-13 (ET)

2025-11-13

07:47:20

Vivani Medical announces Q3 earnings per share of (11c), unchanged from last year.

News

NASDAQ.COM

07-07NASDAQ.COM

Vivani Medical Partners with Novo Nordisk for Semaglutide Implant Evaluation

seekingalpha

07-07seekingalpha

Vivani Medical Partners with Novo Nordisk to Evaluate NanoPortal Implant for Semaglutide

Newsfilter

07-07Newsfilter

Vivani Signs New Agreement with Novo Nordisk for NPM-139 Evaluation

stocktwits

07-02stocktwits

ClearOne's Strategic Shift and Merger with Cortigent

Newsfilter

06-26Newsfilter

Vivani Medical Appoints August Moretti to Board of Directors

Newsfilter

06-25Newsfilter

Vivani Receives Approval for SLIM-1 Clinical Trial in Australia

2 Analyst Rating

Wall Street analysts forecast VANI stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

4.00

Averages

4.00

High

4.00

Current: 0.000

Low

4.00

Averages

4.00

High

4.00

Lake Street

initiated

$4

AI Analysis

2026-06-23

Reason

Lake Street

Price Target

$4

AI Analysis

2026-06-23

initiated

Reason

Lake Street initiated coverage of Vivani Medical with a Buy rating and $4 price target. One of the potential unmet needs in the weight management market is a longer-acting formulation to help patients tackle adherence issues that plague the GLP-1 space, says the analyst, who notes Vivani is taking on the adherence challenge with a long-acting implant technology that would deliver a steady dose of drug for up to 12 months. The firm, which anticipates the initiation and completion of a Phase 1 study of NPM-139, a semaglutide-containing implant, this year, believes a positive readout from the SLIM-1 study will set the company on \"a path toward clinical success and potential value-driving corporate development.\"

H.C. Wainwright

Yi Chen

Buy

downgrade

$4

2026-03-31

Reason

H.C. Wainwright

Yi Chen

Price Target

$4

2026-03-31

downgrade

Buy

Reason

H.C. Wainwright analyst Yi Chen lowered the firm's price target on Vivani Medical to $3.50 from $4 and keeps a Buy rating on the shares after the company recently reported its 2025 results, citing an increased share count for the firm's lowered target. The firm believes NPM-139 is uniquely positioned to potentially offer efficacy comparable to Wegovy while requiring only once or twice yearly administration, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VANI

Unlock Now

Valuation Metrics

The current forward P/E ratio for Vivani Medical Inc (VANI.O) is 0.00, compared to its 5-year average forward P/E of -2.55. For a more detailed relative valuation and DCF analysis to assess Vivani Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.55

Current PE

0.00

Overvalued PE

-1.38

Undervalued PE

-3.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.91

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.18

Undervalued EV/EBITDA

-3.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding VANI

Trading Trends

People Also Watch

Frequently Asked Questions

What is Vivani Medical Inc (VANI) stock price today?

The current price of VANI is 1.35 USD — it has increased 3.85

What is Vivani Medical Inc (VANI)'s business?

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.

What is the price predicton of VANI Stock?

Wall Street analysts forecast VANI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VANI is4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Vivani Medical Inc (VANI)'s revenue for the last quarter?

Vivani Medical Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Vivani Medical Inc (VANI)'s earnings per share (EPS) for the last quarter?

Vivani Medical Inc. EPS for the last quarter amounts to -0.08 USD, decreased -27.27

How many employees does Vivani Medical Inc (VANI). have?

Vivani Medical Inc (VANI) has 42 emplpoyees as of July 08 2026.

What is Vivani Medical Inc (VANI) market cap?

Today VANI has the market capitalization of 116.42M USD.